WASH Stock Analysis: “The Margin Is Fixed, the Book Value Isn’t” — Is the Rerating Already Done?

Washington Trust Bancorp (NASDAQ: WASH) — the Westerly, Rhode Island holding company that calls itself the oldest community bank in the nation — just put up the quarter its December 2024 surgery was supposed to buy. Third-quarter results, released Monday after the close: net income of $19.4 million, diluted EPS of $1.01 against $0.56 a year ago, and a 2.84% net interest margin that has recovered 44 basis points in four quarters. By Tuesday’s premarket the stock was indicated up 6.5% at $38.97, within two dollars of its 52-week high. For a roughly $740 million bank that lost money in 2024, that is a completed narrative arc — exactly when the fine print matters most.

Recall the surgery. On December 20, 2024, Washington Trust sold about $409 million of securities yielding 2.65%, agreed to sell roughly $345 million of residential mortgages at 3.03%, reinvested about $378 million at 5.30%, and earmarked some $352 million to retire wholesale funding costing around 4.50% — taking a roughly $70 million after-tax loss, funded by a $70 million equity raise, that dragged full-year 2024 to a $28.1 million net loss. The promise was that the pain would reappear as margin. It has: 2.40% a year ago, 2.73% in June, 2.84% now, with management guiding 2.85–2.90% for the fourth quarter.

Credit did its part too. The quarter’s headline resolution was a $22.3 million office CRE loan that had been sitting on nonaccrual: $18.5 million returned to accrual and $3.8 million was charged off. Nonaccruals halved to 0.48% of loans. Deposits hit a record $5.44 billion with no brokered money in the stack, FHLB advances fell $80 million to $376 million, and the provision was $1.8 million against $6.8 million a year ago.

Now the catch. The same rate move that flatters an asset-sensitive bank took back the balance sheet: the AOCI loss widened from $77.4 million to $109.8 million as securities fair values fell, total equity dropped $22.7 million to $530.8 million, and book value per share slid from $29.02 to $27.82 — down 4% in the company’s best earnings quarter in years. At the premarket print, buyers are paying about 1.4x a book value that just moved against them. And on Tuesday’s call, management flagged tightening loan spreads — commercial real estate especially — and said no buybacks are planned at current prices.

The Filing

• Net income $19.4M; diluted EPS $1.01 vs $0.83 in Q2 2026 and $0.56 in Q3 2025; ROA 1.17%, ROE 13.89%

• Net interest income $44.7M; NIM 2.84% vs 2.73% last quarter and 2.40% a year ago

• Noninterest income $20.3M — wealth management $11.1M on $7.92B assets under administration, mortgage banking $3.2M

• Provision $1.8M (Q3 2025: $6.8M); net charge-offs $3.9M vs $55K in Q2; nonaccruals 0.48% of loans, from 0.78%

• Loans $5.16B, up $61.8M in the quarter; record deposits of $5.44B, up $77.1M, zero brokered; FHLB advances $376M, down $80M

• Efficiency ratio 59.7% from 63.8%; CET1 11.93% (estimated); quarterly dividend held at $0.56

• Equity $530.8M, down $22.7M; AOCI loss $109.8M from $77.4M; book value per share $27.82 from $29.02

The Context

• The December 2024 repositioning cost about $70M after tax and produced a $28.1M full-year loss; ROA now stands at 1.17% versus 0.64% a year ago.

• A year ago the $0.56 dividend consumed the entire quarter’s $0.56 of EPS; this quarter it takes 55% of it.

• Office CRE: $208.1M across 39 loans — $12.6M classified, $32.2M special mention; lab space adds $28.4M of special mention at a 103% average LTV; about 61% of office balances mature by September 2028.

• Call guidance: Q4 NIM of 2.85–2.90%; expenses up about $1.5M (excluding a $750K charitable contribution); ~5% total and ~10% commercial annualized loan-growth targets.

• The tape: $36.59 Monday close; $38.97 indicated premarket Tuesday (+6.5%); 52-week range $26.52–$40.54; about 19.1M shares for a market cap near $740M.

Bull: The repositioning is doing exactly what shareholders paid $70 million for, and it isn’t finished — eleven more basis points of margin this quarter with a higher guide for next, record core deposits, zero brokered funding, the problem office loan resolved with 83 cents on the dollar back on accrual, fees above $20 million, and an efficiency ratio under 60%. Earnings rose 80% year over year while CET1 sits at 11.93%; the dividend that consumed every penny of EPS a year ago is now covered nearly twice over.

Bear: The easy basis points are banked. Wholesale funding is already down to $376 million, so the Q4 guide leans on deposit repricing just as management concedes loan spreads are tightening. Book value is moving the wrong way — a $32.4 million AOCI swing erased 4% of it in ninety days — and the office book still carries $44.8 million of classified-plus-special-mention exposure, lab space another $28.4 million at a 103% LTV, with roughly 61% of office maturing by late 2028. Charge-offs jumped from $55 thousand to $3.9 million while the reserve ratio slipped to 0.78%. At 1.4x a shrinking book and near the 52-week high, the rerating already assumes clean execution.

Investor Action: Watch Signal.

• The Q4 margin print against the 2.85–2.90% guide — the first quarter where deposit repricing, not wholesale paydown, has to do the lifting.

• Migration in the office and lab book: the $32.2M office special-mention bucket, the $28.4M lab exposure at 103% LTV, and maturity disclosures in the 10-Q.

• Book value: whether BVPS stabilizes above $27.82 once the rate swing settles — the rerating needs the margin and the balance sheet to hold still at the same time.

SCN editorial — independent commentary for information only, not investment advice.